All | Primary treatment | ||||||
Primary surgery | Primary radiotherapy | P value | |||||
N | % | N | % | N | % | ||
All | 1826 | 100 | 352 | 19.3 | 1474 | 80.7 | |
Year of treatment | |||||||
2008–2010 | 478 | 26.2 | 138 | 39.2 | 340 | 23.1 | <0.0001 |
2011–2013 | 544 | 29.8 | 146 | 41.5 | 398 | 27.0 | |
2014–2016 | 500 | 27.4 | 58 | 16.5 | 442 | 30.0 | |
2017–2019 | 304 | 16.7 | 10 | 2.8 | 294 | 20.0 | |
Age (years) | |||||||
Median (IQR) | 41 | (36–46) | 43 | (39–47) | 41 | (36–45) | <0.0001 |
18–34 | 350 | 19.2 | 38 | 10.8 | 312 | 21.2 | |
35–39 | 387 | 22.0 | 62 | 17.6 | 325 | 22.1 | |
40–44 | 485 | 26.6 | 101 | 28.7 | 384 | 26.1 | |
45–49 | 604 | 33.1 | 151 | 43.0 | 453 | 30.7 | |
Race*† | |||||||
White | 361 | 19.8 | 48 | 13.6 | 313 | 21.2 | <0.0001 |
Black | 198 | 10.8 | 15 | 4.3 | 183 | 12.4 | |
Other/unknown | 13 | 0.7 | 11 | 0.8 | |||
NA | 1254 | 68.7 | 289 | 82.1 | 967 | 65.6 | |
Insurance status | |||||||
Commercial | 1215 | 66.5 | 285 | 81.0 | 930 | 63.1 | <0.0001 |
Medicaid | 611 | 33.5 | 67 | 19.0 | 544 | 36.9 | |
Metropolitan statistical area (MSA)† | |||||||
Non-MSA | 188 | 10.3 | 43 | 12.2 | 145 | 9.8 | <0.0001 |
MSA | 984 | 53.9 | 236 | 67.1 | 748 | 50.8 | |
Unknown | 654 | 35.8 | 73 | 20.7 | 581 | 39.4 | |
Region† | |||||||
Northeast | 174 | 9.5 | 46 | 13.1 | 128 | 8.7 | <0.0001 |
North Central | 267 | 14.6 | 57 | 16.2 | 210 | 14.3 | |
South | 537 | 29.4 | 104 | 29.6 | 433 | 29.4 | |
West | 219 | 12.0 | 73 | 20.7 | 146 | 9.9 | |
Unknown | 629 | 34.5 | 72 | 20.5 | 557 | 37.8 | |
Elixhauser comorbidity score | |||||||
0 | 1164 | 63.8 | 222 | 63.1 | 942 | 63.9 | 0.0419 |
1 | 347 | 19.0 | 79 | 22.4 | 268 | 18.2 | |
2 | 157 | 8.6 | 32 | 9.1 | 125 | 8.5 | |
>3 | 158 | 8.7 | 19 | 5.4 | 139 | 9.4 | |
Adjuvant/concurrent chemotherapy | |||||||
No | 308 | 16.9 | 202 | 57.4 | 106 | 7.2 | <0.0001 |
Yes | 1518 | 83.1 | 150 | 42.6 | 1368 | 92.8 |
*To eliminate the small cell of less than 10 patients, we combined counts and percentages in two adjacent cells.
†In the MarketScan dataset, information on race/ethnicity was only available for Medicaid beneficiaries while geographic data, such as MSA and region, was only captured for commercially insured patients.
NA, not applicable.